Advertisement
Advertisement
U.S. Markets open in 6 hrs 4 mins
Advertisement
Advertisement
Advertisement
Advertisement

Cardiol Therapeutics Inc. (CRDL.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.7300+0.1500 (+5.81%)
At close: 03:59PM EST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.5800
Open2.7700
Bid2.6900 x 0
Ask2.7300 x 0
Day's Range2.7000 - 2.8500
52 Week Range2.3200 - 6.1900
Volume167,119
Avg. Volume360,545
Market Cap116.578M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • Newsfile

    Cardiol Therapeutics Announces Closing of US$50 Million Public Offering

    Oakville, Ontario--(Newsfile Corp. - November 5, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease, announced today the closing of its previously announced public offering (the "Offering") of 16,350,000 units of the Company (the "Units") at a price to the public of US$3.07 per Unit for gross proceeds of US$50,194,500, before

  • CNW Group

    Cardiol Therapeutics Announces Pricing of Public Offering of Units

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease (CVD), announced today the pricing of its previously announced public offering (the "Offering") of 16,350,000 units of the Company (the "Units") at a price to the public of US$3.07 per Unit for gross proceeds of US$50,194,500, before deducting the underwriting discounts and commissio

  • CNW Group

    Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease (CVD), has today filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated August 3, 2021 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of units (the "Units"). Each Unit will consist of one Clas

Advertisement
Advertisement